Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.

Services d'Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, France.
Liver international: official journal of the International Association for the Study of the Liver (Impact Factor: 3.87). 04/2005; 25(2):349-56. DOI: 10.1111/j.1478-3231.2005.01095.x
Source: PubMed

ABSTRACT Transjugular intrahepatic portosystemic shunt (TIPS) is a more effective treatment for refractory ascites than large volume paracentesis (LVP), but the magnitude of its effect in terms of control of ascites, encephalopathy and survival has not been established.
This meta-analysis compare TIPS to LVP in terms of control of ascites at 4 and 12 months, encephalopathy and survival at 1 and 2 years.
Five randomized controlled trials involving 330 patients were included. In the TIPS group, control of ascites was more frequently achieved at 4 months (66% vs 23.8%, mean difference: 41.4%, 95% confidence interval (CI): 29.5-53.2%, P < 0.001) and 12 months (54.8% vs 18.9%, mean difference: 35%, 95% CI: 24.9-45.1%, P < 0.001), whereas encephalopathy was higher (54.9% vs 38.1%, mean difference: 17%, 95% CI: 7.3-26.6%, P < 0.001). Survival at 1 year (61.7% vs 56.5%, mean difference: 3.2%, 95% CI: -14.7 to 21.9%) and 2 years (50% vs 42.8%, mean difference: 6.8%, 95% CI: -10 to 23.6%) were not significantly different.
TIPS is a more effective treatment for refractory ascites than LVP. However, TIPS increase encephalopathy and does not improve survival.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In the 25 years since the first TIPS intervention has been performed, technical standards, indications and contraindications have been set up. The previous considerable problem of shunt failure by thrombosis or intimal proliferation in the stent or in the draining heaptic vein has been reduced considerably by the availability of polytetrafluoroethylene [PTFE)-covered stents resulting in reduced rebleeding and improved survival. Unfortunately, most clinical studies have been performed prior to the release of the covered stent and do, therefore, not represent the present state of the art. In spite of this, the TIPS has gained increasing acceptance in the treatment of the various complications of portal hypertension and vascular diseases of the liver.
    Journal of Hepatology 06/2013; · 9.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ascites formation in patients with cirrhosis, portal hypertension, or both usually results from hyperdynamic circulatory dysfunction, where the retention of sodium and water is associated with the activation of the sympathetic and renin-angiotensin-aldosterone systems. The presence of ascites indicates the development of liver decompensation. Furthermore, complications seen in conjunction with ascites such as spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic hydrothorax may result in increased morbidity and mortality. Although nonpharmacological, pharmacological, and surgical approaches have been introduced and clinically practiced, their therapeutic effects are still suboptimal or limited by their potential side effects, such as large-volume paracentesis-induced postparacentesis circulatory dysfunction. Herein, we discuss strategies to prevent and properly manage ascites-related complications, including a review of the literature and controlled studies that assess these strategies.
    Journal of the Chinese Medical Association 03/2013; 76(3):123-30. · 0.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A transjugular intrahepatic portosystemic shunt (TIPS) is an expandable metal stent inserted via the jugular vein that creates a shunt from the portal vein to the systemic circulation via an artificial communication through the liver. It is used to treat complications of portal hypertension. In addition to rescue treatment in variceal bleeding, TIPS can play an important role in prevention of rebleeding. TIPS can improve symptoms if medical treatment of ascites or hepatic hydrothrorax has failed, but may not improve survival. Selected cases of Budd-Chiari syndrome improve with TIPS. This article discusses the indications, evidence, and complications of TIPS.
    Clinics in liver disease 05/2014; 18(2):319-334.

Full-text (2 Sources)

Available from
Jun 4, 2014